| 1 |
中国器官移植发展基金会. 《中国器官移植发展报告(2021)》正式发布[EB/OL]. (2022-12-09)[2023-06-01].
URL
|
| 2 |
Halliday N, Westbrook RH. Liver transplantation: post-transplant management[J]. Br J Hosp Med (Lond), 2017, 78(5)：278-285.
|
| 3 |
Panackel C, Mathew JF, Fawas NM, et al. Immunosuppressive drugs in liver transplant: an insight[J]. J Clin Exp Hepatol, 2022, 12(6)：1557-1571.
|
| 4 |
Schildknecht A, Brauer S, Brenner C, et al. FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells[J]. Proc Natl Acad Sci U S A, 2010, 107(1)：199-203.
|
| 5 |
Fu BM, He XS, Yu S, et al. A tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by activation of antigen-specific CD4+CD25+ T regulatory cells that promotes skin allograft survival in mice[J]. Cell Immunol, 2010, 261(1)：69-76.
|
| 6 |
Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial[J]. Transplantation, 2007, 83(10)：1389-1392.
|
| 7 |
Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation[J]. Transplantation, 2007, 83(4)：425-432.
|
| 8 |
Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma[J]. J Hepatol, 2007, 46(5)：840-848.
|
| 9 |
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2)：433-485.
|
| 10 |
Tan PS, Muthiah MD, Koh T, et al. Asian Liver Transplant Network clinical guidelines on immunosuppression in liver transplantation[J]. Transplantation, 2019, 103(3)：470-480.
|
| 11 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J/CD]. 中华移植杂志：电子版，2021，15(6)：321-328.
|
| 12 |
De Simone P, Fagiuoli S, Cescon M, et al. Use of everolimus in liver transplantation: recommendations from a working group[J]. Transplantation, 2017, 101(2)：239-251.
|
| 13 |
中国医师协会器官移植医师分会肝移植学组，中华医学会器官移植学分会肝移植学组. 西罗莫司在肝癌肝移植中应用的中国专家共识(2020版)[J]. 中华消化外科杂志，2020, 19(6)：589-597.
|
| 14 |
Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation[J]. Transplantation, 1999, 67(4)：505-509.
|
| 15 |
Trotter JF. Sirolimus in liver transplantation[J]. Transplant Proc, 2003, 35(3 Suppl)：193S-200S.
|
| 16 |
Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation[J]. J Hepatol, 2012，56(1)：288-290.
|
| 17 |
Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications[J]. Liver Transpl, 2003, 9(5)：463-468.
|
| 18 |
McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus[J]. Liver Transpl, 2001, 7(8)：701-708.
|
| 19 |
McKenna GJ, Trotter JF. Sirolimus--it doesn′t deserve its bad Rap(a)[J]. J Hepatol, 2012, 56(1)：285-287.
|
| 20 |
周俭，樊嘉，王征，等. 雷帕霉素转换治疗在肝癌肝移植中的初步经验[J]. 中华肝胆外科杂志，2006，12(4)：280-281.
|
| 21 |
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2017 annual data report: liver[J]. Am J Transplant, 2019, 19(Suppl 2)：184-283.
|
| 22 |
何倩颖，王卫星. 依维莫司在肝细胞癌肝移植术后的临床应用[J]. 中国普外基础与临床杂志，2020, 27(6)：759-762.
|
| 23 |
Fischer L, Saliba F, Kaiser GM, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study[J]. Transplantation, 2015, 99(7)：1455-1462.
|
| 24 |
Cholongitas Ε，Goulis I, Theocharidou E, et al. Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience[J]. Hepatol Int, 2014, 8(1)：137-145.
|
| 25 |
Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation[J]. Am J Transplant, 2014, 14(3)：701-710.
|
| 26 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝移植受者肾损伤管理专家共识(2017版)[J/CD]. 中华移植杂志：电子版，2017, 11(3)：130-137.
|
| 27 |
Pacheco MP, Carneiro-D′Albuquerque LA, Mazo DF. Current aspects of renal dysfunction after liver transplantation[J]. World J Hepatol, 2022, 14(1)：45-61.
|
| 28 |
Berkowitz RJ, Engoren MC, Mentz G, et al. Intraoperative risk factors of acute kidney injury after liver transplantation[J]. Liver Transpl, 2022, 28(7)：1207-1223.
|
| 29 |
Zaza G, Granata S, Caletti C, et al. mTOR inhibition role in cellular mechanisms[J]. Transplantation, 2018, 102(2S Suppl 1): S3-S16.
|
| 30 |
Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J]. Am J Transplant, 2012, 12(3)：694-705.
|
| 31 |
Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial[J]. Liver Transpl, 2013, 19(7)：675-689.
|
| 32 |
Buchholz BM, Ferguson JW, Schnitzbauer AA, et al. Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function[J]. Transplantation, 2020, 104(5)：1003-1018.
|
| 33 |
De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial[J]. Liver Transpl, 2009, 15(10)：1262-1269.
|
| 34 |
De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial[J]. Am J Transplant, 2012, 12(11)：3008-3020.
|
| 35 |
Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study[J]. Am J Transplant, 2013, 13(7)：1734-1745.
|
| 36 |
Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT[J]. Am J Transplant, 2012, 12(7)：1855-1865.
|
| 37 |
Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study[J]. Clin Transplant, 2016, 30(6)：741-748.
|
| 38 |
Saliba F, Dharancy S, Salamé E, et al. Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER Registry[J]. Liver Transpl, 2020, 26(11)：1465-1476.
|
| 39 |
Wadei HM, Keaveny AP. Timing of everolimus conversion after liver transplantation: ever early and never late[J]. Liver Transpl, 2020, 26(11)：1395-1397.
|
| 40 |
Sun EJ, Wankell M, Palamuthusingam P, et al. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma[J]. Biomedicines, 2021, 9(11): 1639.
|
| 41 |
Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis[J]. Front Mol Neurosci, 2011, 4：51.
|
| 42 |
Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF[J]. Blood, 2005, 105(11)：4463-4469.
|
| 43 |
Ling S, Zhan Q, Jiang G, et al. E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation[J]. Am J Transplant, 2022，22(10)：2323-2336.
|
| 44 |
Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression[J]. Liver Transpl, 2005, 11(5)：497-503.
|
| 45 |
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5)：857-862.
|
| 46 |
Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6)：1193-1199.
|
| 47 |
Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, et al. Immunosuppressive treatment with mTOR inhibitors for malignancies after liver transplantation: long-term survival retrospective analysis[J]. Transplant Proc, 2020, 52(5)：1507-1510.
|
| 48 |
Yilmaz S, Ince V. The importance of the immunosuppressive regime on hepatocellular carcinoma recurrence after liver transplantation[J]. J Gastrointest Cancer, 2021, 52(4)：1350-1355.
|
| 49 |
Zhang G, Duan B, Li G. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: a systematic review and meta-analysis[J]. Clin Transplant, 2022, 36(12)：e14823.
|
| 50 |
Yan X, Huang S, Yang Y, et al. Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Liver Transpl, 2022, 28(6)：1063-1077.
|
| 51 |
Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function[J]. Am J Transplant, 2010, 10(10)：2252-2262.
|
| 52 |
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1)：116-125.
|
| 53 |
Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors[J]. Ann Surg, 2020, 272(5)：855-862.
|
| 54 |
Lee KW, Kim SH, Yoon KC, et al. Sirolimus prolongs survival after living donor liver transplantation for hepatocellular carcinoma beyond Milan criteria: a prospective, randomised, open-label, multicentre phase 2 trial[J]. J Clin Med, 2020, 9(10)：3264.
|
| 55 |
Al-Ameri A, Yu X, Zheng S. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: systematic review and meta-analysis[J]. Transplant Rev (Orlando), 2022, 36(1)：100676.
|
| 56 |
de′Angelis N, Landi F, Carra MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review[J]. World J Gastroenterol, 2015, 21(39)：11185-11198.
|
| 57 |
Bhoori S, Toffanin S, Sposito C, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle[J]. J Hepatol, 2010, 52(5)：771-775.
|
| 58 |
Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation[J]. Liver Transpl, 2012, 18(1)：45-52.
|
| 59 |
Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids[J]. Australas J Dermatol, 2018, 59(3)：e168-e174.
|
| 60 |
Yang Z, Wang S, Tian XY, et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: preliminary experience[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4)：365-370.
|
| 61 |
王连江，张雅敏. 应重视肝移植术后新发肿瘤的研究[J]. 中华医学杂志，2019, 99(20)：1523-1526.
|
| 62 |
Aberg F, Pukkala E, Höckerstedt K, et al. Risk of malignant neoplasms after liver transplantation: a population-based study[J]. Liver Transpl, 2008, 14(10)：1428-1436.
|
| 63 |
Carenco C, Assenat E, Faure S, et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship[J]. Am J Transplant, 2015, 15(3)：678-686.
|
| 64 |
孟令展，刘振文，朱震宇. 肝移植术后新发恶性肿瘤危险因素的研究进展[J]. 器官移植，2020, 11(5)：646-650.
|
| 65 |
Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients[J]. Transplantation, 2005, 80(6)：749-758.
|
| 66 |
Yakupoglu YK, Buell JF, Woodle S, et al. Individualization of immunosuppressive therapy.Ⅲ. sirolimus associated with a reduced incidence of malignancy[J]. Transplant Proc, 2006, 38(2)：358-361.
|
| 67 |
Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies[J]. Transplantation, 2005, 80(7)：883-889.
|
| 68 |
Dumortier J, Dharancy S, Calmus Y, et al. Use of everolimus in liver transplantation: the French experience[J]. Transplant Rev (Orlando), 2016, 30(3)：161-170.
|
| 69 |
Thimonier E, Guillaud O, Walter T, et al. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease[J]. Clin Transplant, 2014, 28(12)：1339-1348.
|
| 70 |
中华医学会器官移植学分会，中华医学会肝病学分会. 中国肝移植乙型肝炎防治指南(2016版)[J]. 中华肝脏病杂志，2016，24(12)：885-891.
|
| 71 |
王静月，魏来，黄缘，等. 肝移植术后丙型肝炎抗病毒治疗进展[J]. 中华肝脏病杂志，2020，28(5)：452-456.
|
| 72 |
McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression[J]. Am J Transplant, 2011, 11(11)：2379-2387.
|
| 73 |
Kelly MA, Kaplan M, Nydam T, et al. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience[J]. Transplant Proc, 2013, 45(9)：3325-3328.
|
| 74 |
Ma MKM, Yung S, Chan TM. mTOR inhibition and kidney diseases[J]. Transplantation, 2018, 102(2S Suppl 1): S32-S40.
|
| 75 |
中华医学会器官移植学分会. 中国肾移植受者哺乳动物雷帕霉素靶蛋白抑制剂临床应用专家共识[J/CD]. 实用器官移植电子杂志，2018，6(2)：83-89.
|
| 76 |
Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase Ⅱ prospective randomized trial[J]. Am J Transplant, 2014, 14(2)：356-366.
|
| 77 |
Rodríguez-Perálvarez M, Guerrero M, Barrera L, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplantation, 2018, 102(12)：2056-2064.
|
| 78 |
Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria[J]. Transplant Proc, 2008, 40(10)：3548-3553.
|
| 79 |
De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplant Proc, 2014, 46(1)：241-244.
|
| 80 |
Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1)：3-26.
|
| 81 |
Molinari M, Berman K, Meeberg G, et al. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients[J]. Transpl Int, 2010, 23(2)：155-168.
|
| 82 |
Schnitzbauer AA, Sothmann J, Baier L, et al. Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07)[J]. Transplantation, 2015, 99(12)：2565-2575.
|
| 83 |
Levitsky J, Mathew JM, Abecassis M, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients[J]. Hepatology, 2013, 57(1)：239-248.
|
| 84 |
Tsai KF, Li LC, Hsu CN, et al. Effects of conversion from calcineurin inhibitors to sirolimus or everolimus on renal function and possible mechanisms in liver transplant recipients[J]. J Clin Pharmacol, 2019, 59(3)：326-334.
|
| 85 |
Xu SL, Zhang YC, Wang GY, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2016, 40(6)：674-681.
|
| 86 |
Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors[J]. Transplant Rev (Orlando), 2014, 28(3)：126-133.
|
| 87 |
Pallet N, Legendre C. Adverse events associated with mTOR inhibitors[J]. Expert Opin Drug Saf, 2013, 12(2)：177-186.
|
| 88 |
Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation[J]. Expert Opin Drug Saf, 2016, 15(3)：303-319.
|
| 89 |
McDonald MA, Gustafsson F, Almasood A, et al. Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis[J]. Transplant Proc, 2010, 42(7)：2693-2696.
|
| 90 |
Nguyen LS, Vautier M, Allenbach Y, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation[J]. Drug Saf, 2019, 42(7)：813-825.
|
| 91 |
Saliba F, Duvoux C, Gugenheim J, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial[J]. Am J Transplant, 2017, 17(7)：1843-1852.
|
| 92 |
Lamming DW, Sabatini DM. A central role for mTOR in lipid homeostasis[J]. Cell Metab, 2013, 18(4)：465-469.
|
| 93 |
Houde VP, Brûlé S, Festuccia WT, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue[J]. Diabetes, 2010, 59(6)：1338-1348.
|
| 94 |
Charlton M, Rinella M, Patel D, et al. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study[J]. Transplantation, 2017, 101(12)：2873-2882.
|
| 95 |
van der Vliet JA, Willems MC, de Man BM, et al. Everolimus interferes with healing of experimental intestinal anastomoses[J]. Transplantation, 2006, 82(11)：1477-1483.
|
| 96 |
Cooper M, Wiseman AC, Zibari G, et al. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials[J]. Clin Transplant, 2013, 27(6)：E625-E635.
|
| 97 |
Montalti R, Mimmo A, Rompianesi G, et al. Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation[J]. Liver Transpl, 2012, 18(2)：188-194.
|
| 98 |
Campistol JM, de Fijter JW, Flechner SM, et al. mTOR inhibitor-associated dermatologic and mucosal problems[J]. Clin Transplant, 2010, 24(2)：149-156.
|
| 99 |
Peterson DE, O′Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice[J]. Cancer Med, 2016, 5(8)：1897-1907.
|
| 100 |
Pilotte AP, Hohos MB, Polson KM, et al. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors[J]. Clin J Oncol Nurs, 2011, 15(5)：E83-E89.
|
| 101 |
Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity[J]. Transplantation, 2004, 77(8)：1215-1220.
|
| 102 |
Lopez P, Kohler S, Dimri S. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase Ⅲ clinical trial program of everolimus and review of the literature[J]. J Transplant, 2014, 2014：305931.
|
| 103 |
Rodriguez-Pascual J, Cheng E, Maroto P, et al. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma[J]. Anticancer Drugs, 2010, 21(5)：478-486.
|
| 104 |
Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management[J]. Transplant Rev (Orlando), 2008, 22(2)：125-130.
|
| 105 |
Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview[J]. Transpl Int, 2007, 20(4)：305-311.
|
| 106 |
Carta P, Zanazzi M, Minetti EE. Unplanned pregnancies in kidney transplanted patients treated with everolimus: three case reports[J]. Transpl Int, 2015, 28(3)：370-372.
|